CAP
ADAP

Columbia Advisory Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

Columbia Advisory Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36,730
Closed -$4.78K – 91
2025
Q3 		$4.78K Hold
36,730
– – ﹤0.01% 90
2025
Q2 		$8.8K Buy
36,730
+200
+0.5% +$53 0.01% 80
2025
Q1 		$7.2K Buy
36,530
+20,110
+122% +$10.4K 0.01% 72
2024
Q4 		$8.85K Sell
16,420
-15,000
-48% -$10.9K 0.01% 64
2024
Q3 		$29.9K Buy
31,420
+3,333
+12% +$3.78K 0.03% 57
2024
Q2 		$27.4K Buy
28,087
+12,502
+80% +$13.7K 0.03% 52
2024
Q1 		$24.6K Buy
+15,585
New +$18.8K 0.03% 50

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Columbia Advisory Partners's ADAP Position: Q4 2025 in Review

Columbia Advisory Partners sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 36,730 shares — an estimated $4.78K sold.

Columbia Advisory Partners first reported a position in ADAP in Q1 2024 and held it in 7 quarters. The position peaked at $29.9K in Q3 2024. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Columbia Advisory Partners reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Columbia Advisory Partners sold 36,730 Adaptimmune Therapeutics shares in Q4 2025, an estimated $4.78K.
  • Columbia Advisory Partners first reported a position in Adaptimmune Therapeutics in Q1 2024 and held it in 7 quarters.
  • Columbia Advisory Partners's Adaptimmune Therapeutics position peaked at $29.9K in Q3 2024.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Columbia Advisory Partners's 13F filing for Q4 2025, filed 22 Jan 2026.